|
|
| |
|
|
| |
History
November 29, 1978
Biocon’s Founding Day - the start of a biorevolution in India. Over the years, Biocon has evolved from an enzyme-manufacturing company into a fully integrated biopharmaceutical enterprise. Today, we leverage a formidable combination of proprietary fermentation technologies and research skills to develop affordable therapy for unmet medical needs.
1978
Biocon India is incorporated as a joint venture between Biocon Biochemicals Ltd. of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw
1979
Biocon is the first Indian company to manufacture and export enzymes to USA and Europe
1989
Unilever plc. acquires Biocon Biochemicals Ltd. in Ireland and merges it with its subsidiary, Quest International
1989
Biocon is the first Indian biotech company to receive US funding for proprietary technologies
1990
Biocon scales up its in-house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level
1993
Biocon's R&D and manufacturing facilities receive ISO 9001 certification from RWTUV, Germany
1994
Biocon establishes Syngene International Pvt. Ltd. as a Custom research Company (CRC) to address the growing need for outsourced R&D in the pharmaceutical sector
1996
The commercial success of Biocon's proprietary fermentation plant leads to a 3-fold expansion
1996
Biocon leverages its technology platform to enter biopharmaceuticals and statins
1997
Biocon spearheads initiatives in human healthcare through a dedicated manufacturing facility
1998
Unilever inks a deal with ICI to sell its specialty chemicals division of which Quest International is a part. Unilever agrees to sell its shareholding in Biocon to the Indian promoters. Biocon becomes an independent entity
2000
Biocon commissions its first fully automated submerged fermentation plant to produce specialty pharmaceuticals
2000
Biocon establishes Clinigene, India's first Clinical Research Organisation (CRO) to pursue clinical research and development
2001
Biocon becomes the first Indian company to be approved by US FDA for the manufacture of lovastatin, a cholesterol-lowering molecule
2001
Biocon's proprietary bioreactor, PlaFractor™ is granted a US 2001 and world-wide patent
2002
Clinigene's clinical laboratory is the first in India to receive CAP accreditation
2003
Biocon is the first company worldwide to develop human insulin on a Pichia expression system
2004
Biocon creates a buzz in the stock market in March 2004 with its hugely successful IPO. Day 1 on the bourses closes with a market value of $1.11 billion, making Biocon only the second Indian company to cross the $1 billion mark on the first day of listing.
2004
Syngene establishes new research centre
2004
Biocon Limited, announces the launch of INSUGEN®, the new generation bio-insulin, manufactured in Asia's largest human insulin plant.
2004
Biocon Limited and Vaccinex, Inc. announce a broad strategic partnership to discover and co-develop at least four therapeutic antibody products.
2005
Biocon signs a commercial agreement for supply of insulin API to Asia, Africa and the Middle East.
2006
Biocon inaugurates Biocon Biopharmaceuticals, India's largest multi-product Biologics facility at Biocon Park
Biocon inaugurates Biocon Park, India's largest integrated biotechnology hub, comprising an integrated cluster of research laboratories and manufacturing facilities spread across 90 acres in KIADB (Karnataka Industrial Areas Development Board) industrial estate.
Biocon announces a licensing agreement with Bayer HealthCare (BHC) for the exclusive marketing and trademark rights for INSUGEN® for the Chinese market.
Syngene and Innate Pharmaceuticals AB, Umea, Sweden conclude a cooperation agreement to jointly develop, manufacture and market virulence blockers to counteract bacterial diarrhoeal disease.
Biocon launches India's first anti-cancer drug BIOMAb EGFR™.
2007
Biocon and Abu Dhabi based pharmaceutical company Neopharma sign an MOU to establish a JV to manufacture and market a range of biopharmaceuticals for the GCC countries (Gulf Cooperation Council).
Biocon grants exclusive license to Ferozsons Laboratories Limited for marketing BIOMAb EGFR™ in Pakistan.
Biocon announces the launch of its Nephrology Division and a comprehensive portfolio of renal therapy products.
Syngene enters into a research partnership with Bristol-Myers Squibb and completes the ground breaking ceremony of new research facility at Biocon Park.
Biocon signs Memorandum of Understanding with Deakin University, Australia. To establish Deakin Research Institute in Bangalore
Biocon divests enzymes division for USD 115 million to Novozymes. Biocon business portfolio to focus on biopharmaceuticals
Biocon and Abraxis BioScience, announce an agreement wherein Abraxis will license the right to develop a biosimilar version of G-CSF (Granulocyte-Colony Stimulating Factor) in North America and the European Union.
Biocon and Neopharma sign an MOU to establish Neobiocon, a joint venture company in Dubai's biotechnology and research park, Dubiotech.
Biocon and Abraxis BioScience,Inc announce a licensing agreement for the commercialization of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India. Under the terms of the agreement, Biocon will also have the right to market ABRAXANE in Pakistan, Bangladesh, Sri Lanka, United Arab Emirates, Saudi Arabia, Kuwait and certain other Persian Gulf countries.
Biocon presents the results of Phase 1 studies on its oral insulin product, IN-105 at the European Association for Study of Diabetes (EASD) meeting held at Amsterdam. Phase 1 studies were conducted on healthy volunteers who have been administered IN-105 in the form of a tablet. The human clinical data on IN-105 was presented at the session on Novel therapies. Based on these promising results, Biocon intends to now develop this molecule through further clinical trials.
Biocon and Abraxis BioScience, Inc. announce the approval to market ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer by the country's Drug Controller General. Commercial introduction of ABRAXANE in the Indian market is expected in 2008 following the completion of the appropriate importation certifications.
Since its establishment, Biocon Foundation opened four Arogya Raksha Yojana primary healthcare clinics. Biocon Foundation established a cancer hospital along with Dr. Devi Shetty of Narayana Hrudayalaya
2008
Biocon acquires a 70% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of €30 Million |
|
| |
|
|
|
|
